"省税神器，错过再等一年""给娃存2400元，个税多退1080元""个人养老金节税真香，一次能省几千元"……12月16日，北京商报记者注意到，2025年进入倒 计时，保险市场掀起了一股税优保险产品的营销热潮。 不过，热闹背后，不少营销话术暗藏猫腻——将税收优惠等同于"高收益"、夸大节税金额等问题逐渐出现。业内专家表示，在购买保险产品时需关注自身的 保险保障需求，将节税视为一个加分项，而非作出购买决定的唯一依据。 某款产品的宣传帖显示，该产品"复利4.06%"，每年节税1080元。具体介绍提到：一个年缴个税20%的30岁男性一年拿出2400元，连续交10年，那未来10年 他就能每年稳定节税480元：退税的钱加上税优险本身的收益，第11年，复利就达到了惊人的4.06%。 可以看出，保险销售人员宣称的高收益是将税优保险的个税抵扣部分算入产品收益，并非传统意义上基于现金价值增长计算保险产品收益的方式。 李超告诉北京商报记者，部分宣传会将税收优惠金额直接算作投资回报，声称"年化收益率突破4%"。而这种算法甚至基于最高档45%的个人所得税税率， 将退税金额如1080元与保单在特定年份的现金价值简单相加得出高收益率。同时， ...

（原标题：保险营销陷阱：将税优险退税合并计算，称年化收益率超10%） 南方财经全媒体记者 孙诗卉 实习生 徐若萱 临近2025年度个人所得税汇算清缴窗口期，税优健康险和个人养老金保险的营销再度升温。 社交媒体和代理人朋友圈中，"薅国家羊毛最后机会""退税神器""每年能省6480元"等口号频现。 "当年买、次年退税的即时反馈机制，极大降低了消费者的决策门槛。"北京大学应用经济学博士后朱俊 生教授表示。这种快回报体验将抽象的长期保障转化为直观的短期利益，有效提升了销售转化率。 市场热潮背后，一套将税收优惠直接折算为"产品收益率"的话术正在流行。多位业内专家指出，此类宣 传存在混淆概念的误导性，可能使消费者忽视产品本质，陷入"为抵税而投保"的决策误区。 退税补贴非投资回报 在年末的保险营销攻势中，关于税优产品"高收益"的论述最为吸睛。 以年缴2400元的税优健康险为例，适用45%税率的投保人每年可退税1080元。部分销售人员将这1080元 与保单预计的现金价值增长合并，宣称年化收益率可达10%以上。 针对这一现象，对外经济贸易大学创新与风险管理研究中心副主任龙格向21世纪经济报道记者分析指 出，"将最高税率退税额与 ...

临近年末，以"个税节税"为卖点的保险产品营销趋热。近日，不少保险代理人在社交平台发布利用 保险产品进行节税的信息。目前可实现个人所得税节税的保险产品有两类，一类是税优健康险产品，每 年最高可享2400元的抵税额度；另一类是个人养老金保险产品，每年最高可享12000元的抵税额度。 保险销售人员在推介时极力强调税优保险"既能提供健康保障，又能节省个税"的双重功能，将高收 益作为卖点，宣称"最高收益率可达10%以上"。记者调研了解到，所谓高收益往往是将个税抵扣金额计 入收益后计算得出，并非传统意义上保险产品的收益。业内人士认为，此类宣传涉嫌销售误导，消费者 应警惕其中的风险，在购买保险产品时需关注自身的保险保障需求，将节税视为一个加分项，而非作出 购买决定的唯一依据。 ● 本报记者 陈露 "节税+提供保险保障" "在2025年投保生效的个人养老金保险和税优健康险可以享受税优政策，都可以在次年个人所得税 综合所得汇算清缴时办理税前扣除。"保险经纪人苏女士向记者介绍。 苏女士说："目前符合税优政策的健康险主要有医疗险、护理险等险种，护理险一般为2400元起 投，可以充分利用每年最高2400元的抵税额度。个人养老金保险产 ...

说它"被低估"，是因为它明明能做到"10年利益最高达186%（含退税）+享10种重疾保障"，却很少有人 知道；说它"值得囤"，是因为它有国家政策背书，还有诸如中国人保这样的大公司护航，成本低、回报 稳、保障实，简直是打工人的"梦中情保"。 看完这类让打工人疯狂囤货的产品，你会发现：原来真正的好保 最近身边的同事都在悄悄"囤"一类保险——不是网红重疾险，也不是热门医疗险，而是被大多数人忽略 的"税优健康险"。 ...

Summary of Conference Call on Commercial Health Insurance in China Industry Overview - The Chinese medical security system consists of basic medical insurance, supplementary medical insurance, and commercial health insurance, with commercial health insurance accounting for only 4% of the total, indicating significant growth potential [1][2][6]. Key Points and Arguments 1. **Development Focus**: Future development of commercial health insurance should focus on meeting diverse, high-value health needs of customers, emphasizing product innovation, service quality improvement, and expanded coverage [1][3][5]. 2. **Integration with Social Insurance**: The integration of commercial health insurance with social insurance is evolving, with products like million medical insurance gradually merging into the second tier of protection, focusing on non-basic medical insurance coverage [1][4][12]. 3. **Challenges in Commercial Health Insurance**: The industry faces dual challenges from both demand and supply sides, necessitating an increase in insurance payout ratios and the development of products that genuinely meet customer needs, such as high-value critical illness insurance [1][6][8]. 4. **Impact of Inclusive Insurance**: Inclusive insurance products like Huiminbao have raised public awareness of health insurance but have also encroached on the commercial health insurance market, highlighting the potential for tax-advantaged health insurance to grow significantly [1][7][10]. 5. **Critical Illness Insurance Market**: The critical illness insurance market is experiencing challenges due to declining pricing rates and reduced product attractiveness, necessitating reforms to enhance appeal and achieve real transactions [1][8][21][22]. 6. **Internet Consultation Services**: Internet outpatient services play a significant role in commercial health insurance by increasing customer interaction and reducing claims costs, thus benefiting all parties involved [1][19]. Additional Important Insights - **Market Gaps**: There is a substantial gap in the commercial health insurance market, particularly in high-quality medical services outside of basic insurance, especially in first- and second-tier cities [6]. - **Regulatory Support**: Government policies and regulatory improvements are essential for creating a conducive environment for the growth of commercial health insurance [5][12]. - **Long-term Care Insurance**: The long-term care insurance market is still in its infancy, with low coverage levels and significant room for growth, requiring both government and commercial involvement [23][24]. - **Product Pricing**: The pricing of commercial health insurance products needs to be evaluated from multiple stakeholder perspectives to ensure balance and fairness [20]. This summary encapsulates the critical aspects of the conference call regarding the commercial health insurance landscape in China, highlighting both opportunities and challenges within the industry.

Group 1 - In 2021, health insurance premium income reached 880.36 billion yuan, representing a year-on-year growth of 7.7% [1] - Claims expenditure amounted to 408.53 billion yuan, showing a significant year-on-year increase of 39.9% [1] - The insurance industry accumulated 1.3 trillion yuan in long-term health insurance risk reserves for policyholders [1] Group 2 - The insurance sector actively undertook urban and rural residents' major illness insurance, covering 1.22 billion urban and rural residents, with cumulative claims exceeding 60 million [1] - The reimbursement ratio for insured individuals increased by 10 to 15 percentage points [1] - The industry participated in long-term care insurance pilot programs, covering over 100 million people and providing long-term care services for more than 700,000 disabled elderly individuals [1] Group 3 - The China Banking and Insurance Regulatory Commission (CBIRC) plans to further improve the commercial health insurance system [1] - There will be in-depth research on expanding the range of tax-preferred health insurance products and utilizing personal income tax policies effectively [1] - The exploration of a conversion mechanism between life insurance liability and care payment is encouraged to promote the development of commercial long-term care insurance [1]

Investment Rating - The report assigns a "Buy" rating for AIA Group Limited, indicating a positive outlook for the stock [8]. Core Insights - AIA Group reported a strong performance with a 18% year-on-year increase in New Business Value (NBV) and announced a $1.6 billion share buyback plan [8]. - The company achieved a net profit of $6.84 billion, reflecting an 84% year-on-year growth, with a significant increase of 133% in the second half of the year [8]. - The embedded value reached $69 billion, up 4% year-on-year, with an embedded value operating return of 14.9% [8]. - The expected final dividend per share is 130.98 Hong Kong cents, a 10% increase compared to the previous year [8]. Summary by Sections Financial Performance - Total insurance revenue for 2023 was $17.514 billion, with a year-on-year growth of 7.32% [8]. - After-tax operating profit for 2023 was $6.213 billion, showing a decline of 3.24% year-on-year [8]. - Earnings per share (EPS) for 2023 was $0.35, with projections of $0.64 for 2024 and $0.69 for 2025 [8]. New Business Value (NBV) - The annualized new premium (ANP) for the year was $8.61 billion, reflecting a 14% increase year-on-year [8]. - The total NBV for the year was $4.71 billion, with a year-on-year increase of 18% [8]. - The NBV margin improved by 1.9 percentage points to 54.5% [8]. Regional Performance - NBV in Hong Kong increased by 23% to $1.76 billion, accounting for 34.8% of the group's total [8]. - NBV in mainland China reached $1.22 billion, up 20% year-on-year [8]. - The "New Malaysia Thailand" region also showed positive growth in NBV, with increases of 15%, 10%, and 15% respectively [8]. Investment Strategy - The company has shifted its investment strategy, reducing fixed income allocation and increasing equity exposure [8]. - The net investment yield was reported at 4.0%, with a total investment return of 4.9% [8]. Capital Management - AIA Group has completed its previous $12 billion share buyback program and plans to initiate a new $1.6 billion buyback plan to be completed within 2025 [8].